• Publications
  • Influence
Impact of Prior Use or Recent Withdrawal of Oral Antiplatelet Agents on Acute Coronary Syndromes
Background—Oral antiplatelet agents (OAAs) can prevent further vascular events in cardiovascular disease. How prior use or recent discontinuation of OAA affects clinical presentation of acuteExpand
  • 362
  • 12
Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
Background:Inter-patient pharmacokinetic variability can lead to suboptimal drug exposure, and therefore might impact the efficacy of sorafenib. This study reports long-term pharmacokineticExpand
  • 42
  • 2
Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma
Vemurafenib is a BRAF kinase inhibitor approved for first-line treatment of metastatic BRAFV600 -mutant melanoma. However, data on the pharmacokinetic/pharmacodynamic (PK/PD) relationship areExpand
  • 34
  • 1
Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?
Pharmacokinetic/pharmacodynamic data from real-world cohort are sparse in non small–cell lung cancer (NSCLC) patients treated with nivolumab. The aim of this prospective observational study was toExpand
  • 8
  • 1
  • PDF
Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma
BackgroundCirculating tumor DNA (ctDNA) has been reported as a prognostic marker in melanoma. In BRAF V600-mutant melanoma, a plasma under-exposure to vemurafenib could favor emerging resistance butExpand
  • 7
Pharmacokinetics of Caspofungin in Two Patients with Burn Injuries
The pharmacokinetics of caspofungin was investigated for the first time in two patients with burn injuries.
  • 9
Severe skin rash during vemurafenib treatment: A predictive factor of early positive response in metastatic melanoma?
9092 Background: Interindividual variability in pharmacokinetics may influence clinical benefit or toxicity of vemurafenib (VMF) in metastatic melanoma (MM) and identification of predictive factorsExpand
  • 4
Relationship Between Intestinal Function and Exposure to Sorafenib and Sunitinib in Cancer Patients
ABSTRACT Background Variability in exposure to sorafenib (SO) and sunitinib (SU), two oral tyrosine kinase inhibitors (TKI) approved for the treatment of various solid tumours, is large. PlasmaExpand
  • 1
Abstract 4107: Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab efficacy in advanced non-small cell lung cancer
Context Anti-PD1 therapy nivolumab has been approved for the treatment of advanced non-small cell lung cancer (NSCLC). However, a large inter-individual variability in its efficacy has been observed.Expand
Mycophenolic acid drug monitoring in patients with systemic sclerosis associated with diffuse skin and/or pulmonary involvement: A monocentric and retrospective French study:
Objective:To explore pharmacokinetic/pharmacodynamic relationship between mycophenolic acid area under the curve and clinical response at 1 year on skin involvement or interstitial lung disease in ...